PKTX - ProtoKinetix, Incorporated

Other OTC - Other OTC Delayed Price. Currency in USD
0.0000 (0.00%)
At close: 3:22PM EST
Stock chart is not supported by your current browser
Previous Close0.0999
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0999 - 0.0999
52 Week Range0.0500 - 0.3198
Avg. Volume90,703
Market Cap27M
Beta (5Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-0.0070
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    ProtoKinetix AAGP® Dry Eye Therapy Program Launched

    ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces the initiation of a program testing AAGP®, to develop a potential therapy to treat Dry Eye Disease (DED). AAGP® has repeatedly demonstrated anti-inflammatory and cytoprotective properties, and also exhibits pharmaceutical properties beneficial for topical formulations. The eye is extremely sensitive, so before efficacy testing can commence an eye irritation study will be conducted in accordance with both industry and regulatory requirements.

  • Business Wire

    ProtoKinetix AAGP® Operational Update

    ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to provide the following updates regarding upcoming news in key areas. Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will test AAGP® for treatments related to Dry Eye Disease. Join us on Twitter @ProtoKinetix.

  • Business Wire

    ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial

    ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes. All primary safety objectives have been achieved at the midpoint in all study participants. As such, the protocol will now be amended to increase the number of participants in the trial with additional secondary objectives added, including dose escalation to establish optimization criteria for efficacy testing.

  • Business Wire

    ProtoKinetix First in Series of Town Hall Shareholder Meetings

    ProtoKinetix, Incorporated today announces that it will hold the first in a series of Town Hall Meetings. This meeting is being held to update shareholders on the current status of the company’s ongoing research projects.

  • Business Wire

    Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies

    ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has now commenced studies to reveal the benefits of PKX-001 (AAGP®) in cardiac metabolism. As the director of the IMPART cardiometabolic research program, Dr. Pulinilkunnil leverages extensive training in molecular and metabolic sciences from his training at the University of British Columbia, the University of Alberta Heart Institute and Harvard Medical School.

  • Business Wire

    ProtoKinetix Discusses Investor Awareness Campaign and Recent Market Activity

    ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) has been requested by OTC Markets Group to comment on certain recent promotional activity encouraging investors to purchase the Company’s common shares. The Company first became aware of certain promotional third-party newsletter activities from OTC Markets Group on May 2, 2019. Effective May 1, 2019 the Company engaged two investor relations groups to launch a marketing campaign, Burdell Partners LLC and Murdock Capital Partners Corp. The campaign was designed to bring the awareness of the investment community to the Company’s progress and continued successes in multiple health related studies and clinical trials.

  • Business Wire

    ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program

    ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) updates its stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British Columbia. The study is now using 2-animal models and a significantly larger number of animals in both control and AAGP® treated groups for a longer time frame. This study is being conducted to test whether AAGP® treated cells continue to develop into retinal cells.

  • Business Wire

    ProtoKinetix Releases Third in a Series of Scientific Update Videos

    ProtoKinetix, Incorporated announces the launch of the third in a series of informational videos by the Principal Investigators in each field currently being tested.

  • Business Wire

    ProtoKinetix Releases Second in a Series of Scientific Update Videos

    ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the second in a series of informational videos by the Principal Investigators in each field currently being tested. The second video is an update on the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells over a four-week period, we are now expanding the study.